



The Use of Novel Radiotracers in PET Potential Applications for Dose Painting

John Humm, PhD

**Dept. of Medical Physics,
Memorial Sloan-Kettering**

AAPM

Session: Practical Considerations of PET

Thursday 22nd July

Which tracers make sense for radiobiologically driven dose painting?


- (1) FDG since it provides a general guide to metabolically active tumor**
- (2) FLT – provides a signal proportional to the tumor cell proliferation.**
- (3) FMISO – provides the distribution of intra-tumoral hypoxia i.e. pockets of radioresistance**
- (4) Tumor specific Antibodies e.g. ^{124}I -A33,**

What might be the additional value of PET




- **Detection of metastatic spread / staging**
- **Definition of viable target**
- **To measure functional response**
- **Biologically based IMRT**

How do we define ROIs on PET Images?

PET Image Segmentation



This is all well and good provided the distribution of tracer is uniform






Imaging Glucose Metabolism


FDG Uptake in Different Tumors



Lung



Brain



Colon




Rectal


What determines FDG Uptake Heterogeneity?

- Fraction of tumor/stromal cells
- Proliferation rate
- Inflammatory component
- Hypoxia
- Other

Prostate Cancer FDG after single high dose single fraction





FDG
Pre RT



FDG
Post RT


Monitoring Radiation Response in Lung Cancer




$SUV \times V$



Gy




SUV_{max}



Volume

Erdi et al, Eur J Nucl Med. 27(7):861-866, 2000.

Different tracers - different results FDG vs FDHT



FDHT = fluorodihydrotestosterone - A steroid hormone that binds to the androgen receptor involved in signaling tumor cell division

^{18}F FDHT Pre and Post Treatment AR directed therapies

FDHT Jan 24 2008




FDHT Feb 25 2008





Imaging Cellular Proliferation


**Bone
scan**



**FLT for studying
radiation response to
high dose single
fraction RT - prostate
bone met**



**FLT scan
pre RT**




**FLT scan 2 days
post 24 Gy single
fraction RT**




**FLT scan 4
weeks post RT**

P.I. Dr Zelefsky


FLT: L inferior scapula



7/25: before RT SUV 19.5



08/01: one day after RT SUV 12.5






08/22: 21 day after RT SUV 1.5



Hypoxia Imaging

^{18}F -FMISO Scans of H&N Patients






Effect of Threshold

FDG-FMISO2

FDG-FMISO2
T/B = 1.2


FDG-FMISO2
T/M = 1.4






**PET
VOXELS**

Hoechst 33342 - BLUE


Pimonidazole - GREEN



How reproducible are two ^{18}F -FMISO studies performed 3 days apart




Day0
FMISO image





Day3
FMISO image

Plot registered voxel intensities from 1st FMISO image with the 2nd

FMISO2 vs FMISO1




The concept of a GTV_h




IMRT plan for a loco-regionally advanced supraglottic carcinoma:

Delivered Treatment Plan

**Hypothetical Plan
escalating dose to the GTV_h**



70 Gy to GTV




**84 Gy to GTV_h without exceeding
normal tissue tolerances**


IMRT plan for a loco-regionally advanced supraglottic carcinoma:

Delivered Treatment Plan

**Hypothetical Plan
escalating dose to the GTV_h**




70 Gy to GTV



**84 Gy to GTV_h without exceeding
normal tissue tolerances**

Analysis of ^{18}F -FMISO Dynamic PET


$A(t)$ [Bq/cc]



Hypoxia
criterion

Tumor-
Blood
Ratio(T:B)
 ≥ 1.4



not reliable




**Kinetic analysis of Time-Activity
Curves (TAC) is necessary**

*Thorwarth et al,
BMC Cancer. 2005
Dec 1;5:152.*



A compartmental model to mimic FMISO metabolism.




H&N Patient Dynamic PET Images




Parametric Images of ^{18}F -FMISO




Concordance




CT



3hr FMISO



k_3 map




k_1 map

Parametric Images of ^{18}F -FMISO


Discordance




CT




3hr FMISO



k3 map




k1 map




Parametric vs late time-point images Which are correct?




Track 1




Track 2




FLT in Brain Tumors




PET/CT




FLUX/CT



K_1 /CT








K_3 /CT






Tumor Specific Antibodies RadioimmunoPET


Use of PET and intra-operative probes in the O.R.



Does ^{124}I -A33 correspond to microdistribution of tumor location?



PET signal may provide a measure of the number of tumor cells per voxel



Conclusions

- Ideally we would like to perform single time point imaging and directly derive radiobiological information for radiotherapy planning.
- This may not work in all cases.
- FDG easiest to perform but signal uptake dependent upon many factors.
- FLT may be more specific to viable tumor cells.
- Hypoxia tracers are expected to be prognostically relevant.
- Tumor specific antibodies may provide accurate map of tumor cell distribution.



Acknowledgements

MSKCC

Dept of Medical Physics

Sadek Nehmeh, Ph.D.

Jim Mechalakos, Ph.D.

Pat Zanzonico, PhD

Joseph O'Donoghue, PhD

Andrei Pugachev PhD

Shutian Ruan, MD

Sean Carlin, Ph.D.

Bixui Wen, MD

Olivia Squire RN

Kelin Wang, Ph.D.

Clifton Ling, PhD

Nuclear Medicine Service

Steven M Larson, MD

Heiko Schoder, MD

Cyclotron / Radiochemistry Facility

Ron Finn, PhD

Shangde Cai, PhD

Radiation Oncology

Nancy Lee, MD

Fox-Chase Cancer Center

J. Donald Chapman, PhD*

Richard Schneider, PhD